If Sumitomo was willing to pay $2 for CYP years ago, I wouldn't want to accept anything less than $4+, considering all the progress made and the demonstrated clinical efficacy. Not to mention that Cynata holds the only global patents for converting IPSCs to MSCs.
Ann: DFU Clinical Trial Enrolment Complete, page-27
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $34.32M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.0¢ | 18.5¢ | $7.059K | 37.62K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 58798 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 118880 | 1 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| CYP (ASX) Chart |